{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:36:01Z","timestamp":1784082961806,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2001,8,1]]},"DOI":"10.1038\/sj.bmt.1703129","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T16:37:23Z","timestamp":1032280643000},"page":"265-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis"],"prefix":"10.1038","volume":"28","author":[{"given":"M","family":"Vusirikala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SN","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RS","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SJ","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DS","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JP","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FG","family":"Schuening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JS","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SA","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2001,9,4]]},"reference":[{"key":"BF1703129_CR1","first-page":"80","volume":"20","author":"JR Wingard","year":"1993","unstructured":"Wingard JR . Infections in allogeneic bone marrow transplant recipients Semin Oncol 1993 20: 80\u201387","journal-title":"Semin Oncol"},{"key":"BF1703129_CR2","doi-asserted-by":"publisher","first-page":"S776","DOI":"10.1093\/clinids\/12.Supplement_7.S776","volume":"12","author":"DJ Winston","year":"1990","unstructured":"Winston DJ, Ho WG, Champlin RE . Cytomegalovirus infections after allogeneic bone marrow transplantation Rev Infect Dis 1990 12: S776\u2013S792","journal-title":"Rev Infect Dis"},{"key":"BF1703129_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S1083-8791(00)70010-3","volume":"6","author":"RU Osarogiagbon","year":"2000","unstructured":"Osarogiagbon RU, Defor TE, Weisdorf MA et al. CMV antigenemia following bone marrow transplantation: risk factors and outcomes Biol Blood Marrow Transplant 2000 6: 280\u2013288","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1703129_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1086\/514569","volume":"26","author":"A Humar","year":"1998","unstructured":"Humar A, Wood S, Lipton J et al. Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants Clin Infect Dis 1998 26: 606\u2013610","journal-title":"Clin Infect Dis"},{"key":"BF1703129_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/sj.bmt.1701948","volume":"24","author":"H Maltezou","year":"1999","unstructured":"Maltezou H, Whimbey E, Abi-Said D et al. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study Bone Marrow Transplant 1999 24: 665\u2013669","journal-title":"Bone Marrow Transplant"},{"key":"BF1703129_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","volume":"118","author":"JM Goodrich","year":"1993","unstructured":"Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant Ann Intern Med 1993 118: 173\u2013178","journal-title":"Ann Intern Med"},{"key":"BF1703129_CR7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.bmt.1702227","volume":"25","author":"T Mori","year":"2000","unstructured":"Mori T, Okamoto S, Matsuoka S et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation Bone Marrow Transplant 2000 25: 765\u2013769","journal-title":"Bone Marrow Transplant"},{"key":"BF1703129_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","volume":"118","author":"DJ Winston","year":"1993","unstructured":"Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial Ann Intern Med 1993 118: 179\u2013184","journal-title":"Ann Intern Med"},{"key":"BF1703129_CR9","first-page":"783","volume":"13","author":"A Bacigalupo","year":"1994","unstructured":"Bacigalupo A, Tedone E, Van Lint MT et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections Bone Marrow Transplant 1994 13: 783\u2013788","journal-title":"Bone Marrow Transplant"},{"key":"BF1703129_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/sj.bmt.1700498","volume":"19","author":"HG Prentice","year":"1997","unstructured":"Prentice HG, Gluckman E, Powles RL et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group Bone Marrow Transplant 1997 19: 129\u2013133","journal-title":"Bone Marrow Transplant"},{"key":"BF1703129_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM198801143180202","volume":"318","author":"JD Meyers","year":"1988","unstructured":"Meyers JD, Reed EC, Shepp DH et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation New Engl J Med 1988 318: 70\u201375","journal-title":"New Engl J Med"},{"key":"BF1703129_CR12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1086\/515673","volume":"178","author":"M Boeckh","year":"1998","unstructured":"Boeckh M, Gooley TA, Bowden RA . Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia J Infect Dis 1998 178: 1153\u20131157","journal-title":"J Infect Dis"},{"key":"BF1703129_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/clpt.1993.196","volume":"54","author":"S Weller","year":"1993","unstructured":"Weller S, Blum MR, Doucette M et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers Clin Pharmacol Ther 1993 54: 595\u2013605","journal-title":"Clin Pharmacol Ther"},{"issue":"S1","key":"BF1703129_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/jmv.1890410527","volume":"41","author":"D. J. M. Purifoy","year":"1993","unstructured":"Purifoy DJ, Beauchamp LM, de Miranda P et al. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus J Med Virol 1993 (Suppl. 1) 139\u2013145","journal-title":"Journal of Medical Virology"},{"key":"BF1703129_CR15","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1128\/AAC.39.12.2759","volume":"39","author":"J Soul-Lawton","year":"1995","unstructured":"Soul-Lawton J, Seaber E, On N et al. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans Antimicrob Agents Chemother 1995 39: 2759\u20132764","journal-title":"Antimicrob Agents Chemother"},{"key":"BF1703129_CR16","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","volume":"340","author":"D Lowance","year":"1999","unstructured":"Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group New Engl J Med 1999 340: 1462\u20131470","journal-title":"New Engl J Med"},{"key":"BF1703129_CR17","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/ndt\/13.5.1326","volume":"13","author":"B Himmelmann-Jud","year":"1998","unstructured":"Himmelmann-Jud B, Wuthrich RP, Weinreich T, Binswanger U . Successful use of oral valacyclovir in post-transplant cytomegalovirus infection in renal allograft recipients Nephrol Dial Transplant 1998 13: 1326\u20131327","journal-title":"Nephrol Dial Transplant"},{"key":"BF1703129_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1086\/314936","volume":"180","author":"VC Emery","year":"1999","unstructured":"Emery VC, Sabin C, Feinberg JE et al. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204\/Glaxo Wellcome 123\u2013014 International CMV Prophylaxis Study Group J Infect Dis 1999 180: 695\u2013701","journal-title":"J Infect Dis"},{"key":"BF1703129_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1086\/513804","volume":"177","author":"JE Feinberg","year":"1998","unstructured":"Feinberg JE, Hurwitz S, Cooper D et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204\/Glaxo Wellcome 123\u2013014 International CMV Prophylaxis Study Group J Infect Dis 1998 177: 48\u201356","journal-title":"J Infect Dis"},{"key":"BF1703129_CR20","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1128\/jcm.34.5.1337-1339.1996","volume":"34","author":"ML Landry","year":"1996","unstructured":"Landry ML, Ferguson D, Stevens-Ayers T et al. Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence J Clin Microbiol 1996 34: 1337\u20131339","journal-title":"J Clin Microbiol"},{"key":"BF1703129_CR21","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood.V90.6.2502","volume":"90","author":"B Salzberger","year":"1997","unstructured":"Salzberger B, Bowden RA, Hackman RC et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome Blood 1997 90: 2502\u20132508","journal-title":"Blood"},{"key":"BF1703129_CR22","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063","volume":"88","author":"M Boeckh","year":"1996","unstructured":"Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovirversus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study Blood 1996 88: 4063\u20134071","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703129","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T22:19:41Z","timestamp":1648073981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,8,1]]}},"alternative-id":["BF1703129"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703129","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8,1]]},"assertion":[{"value":"18 December 2000","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2001","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2001","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}